Navigation Links
Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Date:7/29/2010

049';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.shionogi.co.jp/">www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCrysts Partner Shionogi Launches Peramivir In Japan Under The Name RAPIACTA
4. Shionogi Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 ... company focused on developing blood-based diagnostic tests for a broad ... its Chief Executive Officer, Cameron Reynolds , is scheduled ... Conference, which is being held September 9-10, 2015 in ... all day on September 10. Wells Fargo ...
(Date:9/1/2015)... BAKERSFIELD, Calif. , Sept. 1, 2015 /PRNewswire/ ... Chronic Care Management (CCM) and Drug Adherence m ... monitoring help automate the process of non face-to-face ... "With this new release of our apps, ... care management services along with our ONCHIT certified ...
(Date:9/1/2015)... , Sept. 1, 2015   Ivenix Inc. ... infusion management system, closed on a $42M round ... Healthcare Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, ... in the round. This financing will support the ... market. Leerink Partners LLC acted as the exclusive ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... CHICAGO, June 3, 2011 Cornerstone Pharmaceuticals ... findings from a Phase I clinical trial of Cornerstone,s ... Leukemia (AML). Data will be presented at the 47th ... http://www.chicago2011.asco.org/ . Cornerstone is a leader in the ...
... June 3, 2011 DURECT Corporation (Nasdaq: DRRX ... be presenting at the Jefferies Healthcare Conference on Tuesday, June ... held at the Grand Hyatt in New York.   ... webcast of the presentation will be available by accessing DURECT,s ...
Cached Medicine Technology:Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia 2Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia 3Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia 4
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... its popular VitaSkin™ collection of products, the VitaSkin™ Exfoliating Peels. This revolutionary collection ... VitaSkin™ pillars: Firm, Bright, Calm, and Clear. , Formulated with alpha hydroxy ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Dr. Trace ... at JourneyLite of Cincinnati. In the last month the FDA has approved two ... Duo ™. These procedures represent the first incisionless, reversible, weight loss procedures available ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... PRO Archiver for Alfresco, a next-generation customer communications archiving solution integrated with ... market-leading technology from Crawford and helps organizations save millions of dollars in ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... interviewed dating men and pick-up artists about their experiences of female beauty, women’s ... bodily concerns, including penis issues, as well as their relationships with other men, ...
(Date:9/1/2015)... ... , ... Anthony J. Tantillo, Esq., Attorney from William Mattar Law Offices, ... in a row. Through nomination, research and strategic evaluation processes, Tantillo continues to ... New York, Tantillo is a Buffalo State College graduate of 1998. Tantillo went ...
Breaking Medicine News(10 mins):Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... SOPHIA ANTIPOLIS, France, May 6 NicOx S.A.,(Euronext ... U.S. phase 2 study,conducted by its partner Pfizer ... doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in,patients ... doses of PF-03187207 demonstrated a clinically significant reduction,in ...
... 1st May 2008: Some of the UKs leading experts ... as RFID in hospitals are already improving the efficiency ... that compatibility problems between hardware and software applications, and ... mean that the NHS is not benefiting as much ...
... Researchers have discovered how a mole develops into melanoma ... in 60-70 percent of tumors. The Penn State ... is necessary for drugs to effectively treat this deadly ... two proteins (V600E)B-Raf and Akt3 communicate with ...
... N.Y., May 6 VirtualCDO acted as the ... of the company to Lawson,Software (St. Paul, MN). ... services, assisted healthcare, hospitality and government,service companies in ... enterprise management services to some 4,000 customers across,40 ...
... - DRAXIS Health Inc. (TSX: DAX),(Nasdaq: DRAX ) ... 2008 on Friday May 9, 2008., Annual and ... meeting (the "Meeting") of shareholders of,DRAXIS is scheduled to ... 5300, TD Bank Tower, Toronto, Ontario, Canada on Friday, ...
... Patients, Safety,Concerns, But Lack Confidence About Best Ways ... As patient safety,incidents in America,s hospitals continue ... hospital CEOs feel strongly confident about practices in,place ... the VHA Foundation,today formally launched the "Health Care ...
Cached Medicine News:Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 2Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 3Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 4Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 5Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 6Health News:Location! Location! Location technologies are improving NHS care 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3Health News:VirtualCDO Acts as M&A Advisor in Sale of VasTech to Lawson Software 2Health News:DRAXIS to Report First Quarter Results on May 9th 2Health News:DRAXIS to Report First Quarter Results on May 9th 3Health News:DRAXIS to Report First Quarter Results on May 9th 4Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 2Health News:VHA Foundation Launches National CEO Patient SafetyNetwork, Starting From the Top to Make Patients Safer 3
Titanium hemi arthroplasty implant for degenerative and post-traumatic arthritis of first metatarsophalangeal joint....
... Cranial Nerve Electrodes provide direct cranial ... Their patented circumferential design provides sensitive ... high-quality, stable real-time recordings. This unique ... during the removal of acoustic neuromas, ...
... of Ad-Techs products, our Sphenoidal Electrodes are manufactured ... available in stainless steel or platinum and feature ... (70 mm) long, 21 gauge (0.83 mm) introducing ... as kits or sets. You can also choose ...
... Stellate Harmonie workstation is a medical device ... high quality video capability, and archiving demands ... review functions A framework that helps organize ... of data A centralized database and powerful ...
Medicine Products: